BIOMAT Database Logo BIOMAT Database Logo

Thromboxane A2 receptor density increases during chronic exposure to thromboxane A2 receptor antagonists after porcine carotid bypass. 1997

T E Brothers, and J G Robison, and B M Elliott, and J M Boggs, and P V Halushka
Department of Surgery, Medical University of South Carolina and the Ralph Henry Johnson Department of Veterans Affairs Medical Center, Charleston, USA.

Domestic swine (n=12 in each group) were randomized to daily treatment with the thromboxane A2 (TXA2) receptor antagonist BMS-180291 (group I), aspirin (group II), or no drug (group III) prior to prosthetic carotid graft implantation. Platelet and arterial wall receptor density were measured by equilibrium binding using 125I-BOP. At 6 weeks, means (s.e.m.) platelet receptor density (pmol/mg) had increased in groups I (3.3(0.6) versus 1.8(0.3); P<0.05) and II (2.6(0.6) versus 1.7(0.2); P<0.05), but not in group III (1.3(0.3) versus 1.2(0.2)). Aortic membrane TXA2 receptor density (fmol/mg) was significantly greater (P<0.05) in groups I (150(50)) and II (68(10)) compared with group III (39(6)). Chronic exposure to a TXA2 receptor antagonist or aspirin is associated with increased platelet and aortic receptor density in pigs.

UI MeSH Term Description Entries
D010080 Oxazoles Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions. Oxazole,1,3-Oxazolium-5-Oxides,Munchnones,1,3 Oxazolium 5 Oxides
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D011093 Polyethylene Terephthalates Polyester polymers formed from terephthalic acid or its esters and ethylene glycol. They can be formed into tapes, films or pulled into fibers that are pressed into meshes or woven into fabrics. Dacron,Nalophan,PET Polymer,Poly(Ethylene Terephtalate),Polyethylene Terephthalate,Tedlar,Dacrons,Nalophans,PET Polymers,Tedlars,Terephthalate, Polyethylene,Terephthalates, Polyethylene
D011138 Polytetrafluoroethylene Homopolymer of tetrafluoroethylene. Nonflammable, tough, inert plastic tubing or sheeting; used to line vessels, insulate, protect or lubricate apparatus; also as filter, coating for surgical implants or as prosthetic material. Synonyms: Fluoroflex; Fluoroplast; Ftoroplast; Halon; Polyfene; PTFE; Tetron. FEP,Fluon,Politef,Polytef,TFE,Teflon,Expanded PTFE,Fluoroplast,GORE-TEX,Goretex,PTFE,Tarflen,GORE TEX,PTFE, Expanded
D001807 Blood Vessel Prosthesis Device constructed of either synthetic or biological material that is used for the repair of injured or diseased blood vessels. Vascular Prosthesis,Blood Vessel Prostheses,Tissue-Engineered Vascular Graft,Graft, Tissue-Engineered Vascular,Grafts, Tissue-Engineered Vascular,Prostheses, Blood Vessel,Prostheses, Vascular,Prosthesis, Blood Vessel,Prosthesis, Vascular,Tissue Engineered Vascular Graft,Tissue-Engineered Vascular Grafts,Vascular Graft, Tissue-Engineered,Vascular Grafts, Tissue-Engineered,Vascular Prostheses,Vessel Prostheses, Blood,Vessel Prosthesis, Blood
D002339 Carotid Arteries Either of the two principal arteries on both sides of the neck that supply blood to the head and neck; each divides into two branches, the internal carotid artery and the external carotid artery. Arteries, Carotid,Artery, Carotid,Carotid Artery
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006083 Graft Occlusion, Vascular Obstruction of flow in biological or prosthetic vascular grafts. Graft Restenosis, Vascular,Vascular Graft Occlusion,Vascular Graft Restenosis,Graft Restenoses, Vascular,Occlusion, Vascular Graft,Restenosis, Vascular Graft
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

T E Brothers, and J G Robison, and B M Elliott, and J M Boggs, and P V Halushka
Thromboxane A2 receptor antagonists.
September 1991, Medicinal research reviews,
T E Brothers, and J G Robison, and B M Elliott, and J M Boggs, and P V Halushka
Pharmacology of thromboxane A2 receptor antagonists.
January 1989, Zeitschrift fur Kardiologie,
T E Brothers, and J G Robison, and B M Elliott, and J M Boggs, and P V Halushka
Thromboxane A2/prostaglandin H2 receptor antagonists.
January 1990, Methods in enzymology,
T E Brothers, and J G Robison, and B M Elliott, and J M Boggs, and P V Halushka
Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses.
June 1995, Circulation,
T E Brothers, and J G Robison, and B M Elliott, and J M Boggs, and P V Halushka
Thromboxane A2 receptor antagonists inhibit endothelium-dependent contractions.
June 1990, Hypertension (Dallas, Tex. : 1979),
T E Brothers, and J G Robison, and B M Elliott, and J M Boggs, and P V Halushka
Testosterone increases thromboxane A2 receptor density and responsiveness in rat aortas and platelets.
September 1994, The American journal of physiology,
T E Brothers, and J G Robison, and B M Elliott, and J M Boggs, and P V Halushka
Azulene derivatives: new non-prostanoid thromboxane A2 receptor antagonists.
September 1990, Journal of medicinal chemistry,
T E Brothers, and J G Robison, and B M Elliott, and J M Boggs, and P V Halushka
Experimental and clinical action of thromboxane A2 receptor antagonists.
January 1990, Contributions to nephrology,
T E Brothers, and J G Robison, and B M Elliott, and J M Boggs, and P V Halushka
Thromboxane A2 receptor-specific antagonism in hypothermic cardiopulmonary bypass.
April 1994, The Annals of thoracic surgery,
T E Brothers, and J G Robison, and B M Elliott, and J M Boggs, and P V Halushka
Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2)-receptor antagonists.
September 2014, ACS medicinal chemistry letters,
Copied contents to your clipboard!